Aduro BioTech, a Berkeley, Calif.-based, private, clinical-stage biotechnology company focused on immunotherapy for cancer, has entered into its second agreement with Janssen Biotech, part of Johnson & Johnson, granting an exclusive, worldwide license to certain product candidates engineered for the treatment of lung cancer and certain other cancers based on its novel LADD immunotherapy platform.

Under the agreement, facilitated by the Johnson & Johnson Innovation Center in California, Aduro will receive a $30 million up-front payment and is eligible to receive significant development, regulatory and commercialization milestone payments up to a potential total of $817 million. In addition, Aduro is eligible to receive high single-digit to double-digit tiered royalties on worldwide net sales upon successful launch and commercialization.

Janssen will have exclusive rights to develop and commercialize LADD product candidates in lung cancer and will assume responsibility for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. Aduro may provide assistance in any of these areas upon request and will receive additional fees for these support activities.

In May, Aduro announced its first agreement with Janssen Biotech, granting the company an exclusive, worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel LADD immunotherapy platform. Under that agreement, also facilitated by the Johnson & Johnson Innovation Center in California, Aduro is eligible to receive up to $365 million in upfront and development and commercialization milestones.